The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Bruton Tyrosine Kinase (BTK) Inhibitor Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Bruton Tyrosine Kinase (BTK) Inhibitor Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029

Publishing Date : Jul, 2023

License Type :
 

Report Code : 1752633

No of Pages : 108

Synopsis
The global Bruton Tyrosine Kinase (BTK) Inhibitor market size was valued at USD 911.6 million in 2022 and is forecast to a readjusted size of USD 1825.9 million by 2029 with a CAGR of 10.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development. Currently, BTK inhibitors are mainly applied in the treatments of hematological malignancies.

This report is a detailed and comprehensive analysis for global Bruton Tyrosine Kinase (BTK) Inhibitor market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Bruton Tyrosine Kinase (BTK) Inhibitor market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Bruton Tyrosine Kinase (BTK) Inhibitor market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Bruton Tyrosine Kinase (BTK) Inhibitor market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Bruton Tyrosine Kinase (BTK) Inhibitor market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Bruton Tyrosine Kinase (BTK) Inhibitor
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global Bruton Tyrosine Kinase (BTK) Inhibitor market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Aptose Eiosciences, BeiGene, Hanmi Phamaceutical and Eli Lilly, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Bruton Tyrosine Kinase (BTK) Inhibitor market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

  • Tablet
  • Capsule

Market segment by Application

  • Chronic Lymphocytic Leukemia (CLL)
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Waldenstrom Macroglobulinemia
  • Other Selective B Cell Malignancies
  • Chronic Graft-versus-host Disease
  • Others

Major players covered

  • Pfizer
  • Aptose Eiosciences
  • BeiGene
  • Hanmi Phamaceutical
  • Eli Lilly
  • Merck
  • Ono Phamaceutical
  • AbbVie
  • Zhejiang DTRM Biopharma
  • AstraZeneca
  • Biogen

Market segment by region, regional analysis covers

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
  • South America (Brazil, Argentina, Colombia, and Rest of South America)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Bruton Tyrosine Kinase (BTK) Inhibitor product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Bruton Tyrosine Kinase (BTK) Inhibitor, with price, sales, revenue and global market share of Bruton Tyrosine Kinase (BTK) Inhibitor from 2018 to 2023.
Chapter 3, the Bruton Tyrosine Kinase (BTK) Inhibitor competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Bruton Tyrosine Kinase (BTK) Inhibitor breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Bruton Tyrosine Kinase (BTK) Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Bruton Tyrosine Kinase (BTK) Inhibitor.
Chapter 14 and 15, to describe Bruton Tyrosine Kinase (BTK) Inhibitor sales channel, distributors, customers, research findings and conclusion.

Index

1 Market Overview
1.1 Product Overview and Scope of Bruton Tyrosine Kinase (BTK) Inhibitor
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Tablet
1.3.3 Capsule
1.4 Market Analysis by Application
1.4.1 Overview: Global Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Chronic Lymphocytic Leukemia (CLL)
1.4.3 Follicular Lymphoma
1.4.4 Mantle Cell Lymphoma
1.4.5 Waldenstrom Macroglobulinemia
1.4.6 Other Selective B Cell Malignancies
1.4.7 Chronic Graft-versus-host Disease
1.4.8 Others
1.5 Global Bruton Tyrosine Kinase (BTK) Inhibitor Market Size & Forecast
1.5.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity (2018-2029)
1.5.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Bruton Tyrosine Kinase (BTK) Inhibitor Product and Services
2.1.4 Pfizer Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Pfizer Recent Developments/Updates
2.2 Aptose Eiosciences
2.2.1 Aptose Eiosciences Details
2.2.2 Aptose Eiosciences Major Business
2.2.3 Aptose Eiosciences Bruton Tyrosine Kinase (BTK) Inhibitor Product and Services
2.2.4 Aptose Eiosciences Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Aptose Eiosciences Recent Developments/Updates
2.3 BeiGene
2.3.1 BeiGene Details
2.3.2 BeiGene Major Business
2.3.3 BeiGene Bruton Tyrosine Kinase (BTK) Inhibitor Product and Services
2.3.4 BeiGene Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 BeiGene Recent Developments/Updates
2.4 Hanmi Phamaceutical
2.4.1 Hanmi Phamaceutical Details
2.4.2 Hanmi Phamaceutical Major Business
2.4.3 Hanmi Phamaceutical Bruton Tyrosine Kinase (BTK) Inhibitor Product and Services
2.4.4 Hanmi Phamaceutical Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Hanmi Phamaceutical Recent Developments/Updates
2.5 Eli Lilly
2.5.1 Eli Lilly Details
2.5.2 Eli Lilly Major Business
2.5.3 Eli Lilly Bruton Tyrosine Kinase (BTK) Inhibitor Product and Services
2.5.4 Eli Lilly Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Eli Lilly Recent Developments/Updates
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business
2.6.3 Merck Bruton Tyrosine Kinase (BTK) Inhibitor Product and Services
2.6.4 Merck Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Merck Recent Developments/Updates
2.7 Ono Phamaceutical
2.7.1 Ono Phamaceutical Details
2.7.2 Ono Phamaceutical Major Business
2.7.3 Ono Phamaceutical Bruton Tyrosine Kinase (BTK) Inhibitor Product and Services
2.7.4 Ono Phamaceutical Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Ono Phamaceutical Recent Developments/Updates
2.8 AbbVie
2.8.1 AbbVie Details
2.8.2 AbbVie Major Business
2.8.3 AbbVie Bruton Tyrosine Kinase (BTK) Inhibitor Product and Services
2.8.4 AbbVie Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 AbbVie Recent Developments/Updates
2.9 Zhejiang DTRM Biopharma
2.9.1 Zhejiang DTRM Biopharma Details
2.9.2 Zhejiang DTRM Biopharma Major Business
2.9.3 Zhejiang DTRM Biopharma Bruton Tyrosine Kinase (BTK) Inhibitor Product and Services
2.9.4 Zhejiang DTRM Biopharma Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Zhejiang DTRM Biopharma Recent Developments/Updates
2.10 AstraZeneca
2.10.1 AstraZeneca Details
2.10.2 AstraZeneca Major Business
2.10.3 AstraZeneca Bruton Tyrosine Kinase (BTK) Inhibitor Product and Services
2.10.4 AstraZeneca Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 AstraZeneca Recent Developments/Updates
2.11 Biogen
2.11.1 Biogen Details
2.11.2 Biogen Major Business
2.11.3 Biogen Bruton Tyrosine Kinase (BTK) Inhibitor Product and Services
2.11.4 Biogen Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Biogen Recent Developments/Updates
3 Competitive Environment: Bruton Tyrosine Kinase (BTK) Inhibitor by Manufacturer
3.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Manufacturer (2018-2023)
3.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Manufacturer (2018-2023)
3.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Bruton Tyrosine Kinase (BTK) Inhibitor by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Bruton Tyrosine Kinase (BTK) Inhibitor Manufacturer Market Share in 2022
3.4.2 Top 6 Bruton Tyrosine Kinase (BTK) Inhibitor Manufacturer Market Share in 2022
3.5 Bruton Tyrosine Kinase (BTK) Inhibitor Market: Overall Company Footprint Analysis
3.5.1 Bruton Tyrosine Kinase (BTK) Inhibitor Market: Region Footprint
3.5.2 Bruton Tyrosine Kinase (BTK) Inhibitor Market: Company Product Type Footprint
3.5.3 Bruton Tyrosine Kinase (BTK) Inhibitor Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Market Size by Region
4.1.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Region (2018-2029)
4.1.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value by Region (2018-2029)
4.1.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Average Price by Region (2018-2029)
4.2 North America Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value (2018-2029)
4.3 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value (2018-2029)
4.4 Asia-Pacific Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value (2018-2029)
4.5 South America Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value (2018-2029)
4.6 Middle East and Africa Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Type (2018-2029)
5.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value by Type (2018-2029)
5.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Application (2018-2029)
6.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value by Application (2018-2029)
6.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Average Price by Application (2018-2029)
7 North America
7.1 North America Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Type (2018-2029)
7.2 North America Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Application (2018-2029)
7.3 North America Bruton Tyrosine Kinase (BTK) Inhibitor Market Size by Country
7.3.1 North America Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Country (2018-2029)
7.3.2 North America Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Type (2018-2029)
8.2 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Application (2018-2029)
8.3 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Market Size by Country
8.3.1 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Country (2018-2029)
8.3.2 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Bruton Tyrosine Kinase (BTK) Inhibitor Market Size by Region
9.3.1 Asia-Pacific Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Type (2018-2029)
10.2 South America Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Application (2018-2029)
10.3 South America Bruton Tyrosine Kinase (BTK) Inhibitor Market Size by Country
10.3.1 South America Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Country (2018-2029)
10.3.2 South America Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitor Market Size by Country
11.3.1 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitor Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitor Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Bruton Tyrosine Kinase (BTK) Inhibitor Market Drivers
12.2 Bruton Tyrosine Kinase (BTK) Inhibitor Market Restraints
12.3 Bruton Tyrosine Kinase (BTK) Inhibitor Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Bruton Tyrosine Kinase (BTK) Inhibitor and Key Manufacturers
13.2 Manufacturing Costs Percentage of Bruton Tyrosine Kinase (BTK) Inhibitor
13.3 Bruton Tyrosine Kinase (BTK) Inhibitor Production Process
13.4 Bruton Tyrosine Kinase (BTK) Inhibitor Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Bruton Tyrosine Kinase (BTK) Inhibitor Typical Distributors
14.3 Bruton Tyrosine Kinase (BTK) Inhibitor Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Published By : GlobalInfoResearch

Why ‘The Market Reports’